Anticipating risk. Transforming prevention.
At ALIA Health Insights, we are developing AI-powered technology to identify disease risk from existing medical images, starting with breast cancer.
Our first development, MammoRisk+, aims to transform mammography into a source of information for estimating future risk and supporting more personalized prevention and follow-up strategies.
ABOUT US
AI-powered predictive medicine
ALIA Health Insights is a spin-off from Tecnológico de Monterrey developing artificial intelligence solutions to transform existing medical images into clinically relevant risk information.
We combine clinical research, artificial intelligence, and technology development to advance toward more predictive and personalized medicine.
OUR FIRST DEVELOPMENT
MammoRisk+
MammoRisk+ is an artificial intelligence technology in development designed to estimate future breast cancer risk from digital mammograms.
Built on research and real-world clinical data, the model analyzes information contained within the image to generate a quantitative risk estimate that complements clinical assessment.
We are currently advancing its technological development, clinical validation, and regulatory readiness.
HOW IT WORKS
From medical images to Risk Information
1. Image
The digital mammogram serves as the input for analysis.
2. Artificial intelligence
The model analyzes imaging patterns associated with future breast cancer risk.
3. Risk estimation
A quantitative risk estimate is generated to complement available clinical information.
4. Clinical decision-making
The information is designed to support healthcare professionals in developing more personalized prevention and follow-up strategies.
CLINICAL INTEGRATION
From artificial intelligence to clinical practice.
ALIA Health develops its technology in two complementary layers: an AI risk model and a clinical platform that delivers that information to healthcare professionals.
With a clinical-first approach, we design our technology to integrate seamlessly into existing healthcare workflows and systems.
Daly Avendaño, MD, PhD
Chief Medical & Scientific Officer · Co-Founder
OUR TEAM
José Tamez Peña, PhD
AI Scientific Lead · Co-Founder
Servando Cardona Huerta, MD, PhD
Clinical Strategy · Co-Founder
Edgar Núñez García
CEO
Spin-off from:
Backed by:
InnovaFest Monterrey 2026
ALIA Health participated in InnovaFest Monterrey 2026, connecting our technology with the innovation and entrepreneurship ecosystem.
News
2026 Mexican Innovation Award
%204_44_20%E2%80%AFa_m_.png)
ALIA Health received the 2026 Mexican Innovation Award in the Health and Precision Medicine category.
The Research Behind ALIA
Conecta Tec features the research developed at Tecnológico de Monterrey to anticipate breast cancer risk using artificial intelligence—the scientific foundation that led to the development of ALIA Health and MammoRisk+.
LET’S CONNECT
Let’s build the future of predictive medicine.
ALIA Health is entering the next stage of its development and growth.
We are looking to connect with investors, healthcare institutions, and strategic partners interested in transforming how we anticipate risk and advance more personalized care.
FOLLOW US!
